Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Excessive Daytime Sleepiness Clear all
No Longer Available No phase listed Expanded access

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy

NCT03433131
View directory record Official record
Conditions
Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Interventions
Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
71
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

NCT07540897
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Miami, Florida • Winter Park, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Phase 3 Interventional

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

NCT07484217
View directory record Official record
Conditions
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions
Solriamfetol 150 MG, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
13
States / cities
Chino, California • Redlands, California • Walnut Creek, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Phase 2 Interventional

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

NCT07096674
View directory record Official record
Conditions
Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia
Interventions
ORX750
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
19
States / cities
Auburn, Alabama • Santa Ana, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Withdrawn Not applicable Interventional

Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease

NCT00393562
View directory record Official record
Conditions
Parkinson's Disease
Interventions
modafinil, methylphenidate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 4 Interventional

A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes in Participants With Idiopathic Hypersomnia or Narcolepsy

NCT05875974
View directory record Official record
Conditions
Idiopathic Hypersomnia, Narcolepsy
Interventions
JZP258 (XYWAV)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Not applicable Interventional

Whole Food Plant-based Diet Effect on Obstructive Sleep Apnea

NCT06395181
View directory record Official record
Conditions
Obstructive Sleep Apnea, Daytime Sleepiness
Interventions
Whole Food Plant-Based Diet
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial to Assess Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilepsy

NCT01190098
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Lacosamide, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Jul 21, 2026, 7:10 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Project REST: Club Sports

NCT07103759
View directory record Official record
Conditions
Poor Quality Sleep
Interventions
Refrain from caffeine techniques, Project REST Platform
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

NCT03624920
View directory record Official record
Conditions
Parkinson Disease
Interventions
THN102 Dosage A, THN102 Dosage B, THN102 Dosage C
Drug
Lead sponsor
Theranexus
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Sleep and Morning Wellbeing Study

NCT07311434
View directory record Official record
Conditions
Sleep, Relaxation, Stress, Daytime Sleepiness
Interventions
Sleep Supplement
Dietary Supplement
Lead sponsor
Athletic Greens International
Industry
Eligibility
22 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Determine the Effectiveness of Pillar Palatal Implants to Treat Obstructive Sleep Apnea

NCT00307957
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Pillar Palatal Implants
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Indianapolis, Indiana • Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 2 Interventional Results available

A Study Of A Novel Compound For Excessive Daytime Sleepiness Associated With Narcolepsy

NCT01006122
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Narcolepsy
Interventions
Placebo, PF-03654746
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Jul 21, 2026, 7:10 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

NCT07082829
View directory record Official record
Conditions
Excessive Daytime Sleepiness
Interventions
ORX142 Tablets, Placebo Tablets
Drug · Other
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Lincoln, Nebraska • Eatontown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

NCT03959189
View directory record Official record
Conditions
Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions
ERX-963, Placebo
Drug
Lead sponsor
Expansion Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management

NCT00801892
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Diabetes Mellitus, Type 2
Interventions
Continuous Positive Airway Pressure (CPAP), Sham- Continuous Positive Airway Pressure (Sham-CPAP)
Device
Lead sponsor
Eileen R. Chasens
Other
Eligibility
40 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)

NCT05113745
View directory record Official record
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy

NCT00066170
View directory record Official record
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness

NCT01124851
View directory record Official record
Conditions
Sleep Disorder
Interventions
ABT-652, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Glendale, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2011 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Litebook EDGE™ Phototherapy on Academic Performance and Brain Activity

NCT05383690
View directory record Official record
Conditions
Sleepiness, Daytime
Interventions
LED bright light treatment device
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 3 Interventional Results available

Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

NCT02720744
View directory record Official record
Conditions
Excessive Daytime Sleepiness, Cataplexy, Narcolepsy
Interventions
FT218, Placebo
Drug
Lead sponsor
Avadel
Industry
Eligibility
16 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
38
States / cities
Anniston, Alabama • Auburn, Alabama • Birmingham, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 21, 2026, 7:10 AM EDT
Enrolling by invitation No phase listed Observational

Adult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities.

NCT06336525
View directory record Official record
Conditions
Sleep Apnea, Insomnia, Sleep Deprivation, Sleep Disorders, Circadian Rhythm, Sleepiness, Excessive Daytime, Fatigue
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
25 Years to 65 Years
Enrollment
3,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Jul 21, 2026, 7:10 AM EDT
Active, not recruiting Not applicable Interventional

Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

NCT02909192
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Light Therapy Device
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 21, 2026, 7:10 AM EDT
Completed Phase 1 Interventional

Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP)

NCT04091425
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Jul 21, 2026, 7:10 AM EDT